Novartis UK and the company's division, Sandoz UK, today announced that they have been officially certified by the Top Employers Institute for their “exceptional employee offerings both within the UK and throughout Europe”. Novartis UK has been consistently recognized for its dedication to employees in the UK and Europe. It is the second year in a row that Sandoz UK has been certified as a UK and Europe Top Employer. The Top Employers Institute is a global certification company that recognizes excellence in the conditions that employers create for their people. The Institute assessed the employee offerings of Novartis UK and Sandoz UK based on the following criteria:
• Talent strategy ⨠• Workforce planning ⨕ On-boarding⨠• Learning and development⨠• Performance management⨠• Leadership development ⨕ Career and succession management⨠• Compensation and benefits⨠• Culture David Plink, CEO of the Top Employers Institute, commented: “Optimal employee conditions ensure that people can develop themselves personally and professionally. Our comprehensive research concluded that Novartis UK and Sandoz UK both provide outstanding employment environments and offer a wide range of creative initiatives, from secondary benefits and working conditions, to performance-management programmes that are well thought out and truly aligned with the culture of their company.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.